# MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002)

> **NCT03552536** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 5 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** MK-8583

## Key facts

- **NCT ID:** NCT03552536
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-07
- **Primary completion:** 2019-03-11
- **Final completion:** 2019-03-11
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2020-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03552536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03552536, "MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002)". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03552536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*